<?xml version="1.0" encoding="UTF-8"?>
<p>Toll-like receptors 3 (TLR3) and 7 (TLR7) play an important role in the innate immune response against HIV-1 and SARS-CoV-2 [
 <xref rid="B67-molecules-25-02944" ref-type="bibr">67</xref>,
 <xref rid="B68-molecules-25-02944" ref-type="bibr">68</xref>,
 <xref rid="B69-molecules-25-02944" ref-type="bibr">69</xref>,
 <xref rid="B70-molecules-25-02944" ref-type="bibr">70</xref>,
 <xref rid="B71-molecules-25-02944" ref-type="bibr">71</xref>]. The polymorphism rs3775291 of the TLR3 receptor is associated with protection against HIV-1 [
 <xref rid="B67-molecules-25-02944" ref-type="bibr">67</xref>,
 <xref rid="B68-molecules-25-02944" ref-type="bibr">68</xref>]. TLR3 agonists increase the anti-HIV immune response induced by vaccination [
 <xref rid="B69-molecules-25-02944" ref-type="bibr">69</xref>]. TLR7 agonists increase the anti-HIV-1 immune response, the activation of HIV-1 expression, and the inhibition of HIV-1 replication, which may help to treat latent infections [
 <xref rid="B70-molecules-25-02944" ref-type="bibr">70</xref>]. The role of TLR3 and TLR7 in the pathogenesis of COVID-19 is discussed in the study by Sallenave [
 <xref rid="B71-molecules-25-02944" ref-type="bibr">71</xref>]. 
</p>
